# Acrivon Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acrivon-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Watertown, US
- Website: www.acrivon.com
- Total disclosed funding: $100M
- Latest round: Series B (Nov 9, 2021)
- Investors on record: 12

## About

Based in Massachusetts, US, and founded in 2018 by its CEO, Peter Blume-Jensen, and co-founder Kristina Masson, Acrivon Therapeutics, Inc. operates as a clinical-stage oncology therapeutics company that uses the Predictive Precision Proteomics (AP3) technology platform to help reduce toxicity by developing chemically designed drugs by matching patients with the active disease-driving processes of cancer. In November 2021, Acrivon Therapeutics, Inc. raised USD 100 in series B funding led by Surveyor Capital and Wellington Management, with Acorn BioVentures, BB Pureos Bioventures, HBM Partners, Healthcor Partners Management, Marshall Wace, Perceptive Advisors, RA Capital, and Sands Capital Ventures. 

Acrivon Therapeutics, Inc. leverages its proprietary phosphoproteomics technology, called Acrivon Precision Predictive Proteomics, in the development of its pipeline of oncology drugs. The AP3 platform enables the creation of drug-specific proprietary OncoSignature®.

Acrivon Therapeutics, Inc. will use the series B funding to support the clinical development of a cancer asset it licensed and advance its precision proteomics platform.

## Funding rounds

- Series B, Nov 9, 2021, $100M — HBM Partners, Alexandria Venture Investments, Marshall Wace, Wellington Management, HealthCor Group, RA Capital Management, Chione, Perceptive Advisors, Sands Capital Alternatives, Surveyor Capital, Acorn Bioventures, Pureos Bioventures

## Investors

- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series B
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B
- HealthCor Group (https://capitalatlas.ai/funds/healthcor-group) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Chione — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series B
- Surveyor Capital — Series B
- Acorn Bioventures (https://capitalatlas.ai/funds/acorn-bioventures) — Series B
- Pureos Bioventures (https://capitalatlas.ai/funds/pureos-bioventures) — Series B